Pharmacological LRRK2 kinase inhibition induces LRRK2 protein destabilization and proteasomal degradation

Leucine-rich repeat kinase 2 (LRRK2) kinase activity is increased in several pathogenic mutations, including the most common mutation, G2019S, and is known to play a role in Parkinson’s disease (PD) pathobiology. This has stimulated the development of potent, selective LRRK2 kinase inhibitors as one...

Descripción completa

Detalles Bibliográficos
Autores principales: Lobbestael, E., Civiero, L., De Wit, T., Taymans, J.-M., Greggio, E., Baekelandt, V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034242/
https://www.ncbi.nlm.nih.gov/pubmed/27658356
http://dx.doi.org/10.1038/srep33897

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5034242/
https://www.ncbi.nlm.nih.gov/pubmed/27658356
http://dx.doi.org/10.1038/srep33897

Ejemplares similares